View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 10, 2020

Avastin and Tecentriq combination wins approval in China and Europe

By GlobalData Healthcare

On 29 October, Roche’s combination of Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, and Tecentriq (atezolizumab), a programmed death-ligand 1 (PD-L1), received approval from the China National Medical Products Administration (NMPA) as a first-line treatment for advanced hepatocellular carcinoma (HCC). Soon after, on 2 November, the combination was approved by the European Commission for the same use. It followed quickly after a 17 September recommendation by the Committee for Medicinal Products for Human Use (CHMP). Recent approvals for Avastin plus Tecentriq mark the availability of the combination across US, Europe, Japan, and China.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Earlier this year, on 29 May, Roche announced the first approval of Avastin and Tecentriq for first-line advanced HCC by the Food and Drug Administration (FDA), and a few months later, Chugai Pharmaceutical, a subsidiary controlled by Roche, announced the approval of Avastin and Tecentriq by the Ministry of Health, Labour and Welfare (MHLW) in Japan on 25 September. GlobalData interviewed KOLs from five major European pharmaceutical markets (5EU: France, Germany, Italy, Spain, and the UK) and China who believed that the majority of patients would receive Avastin plus Tecentriq in the first-line setting, except for patients with a contraindication to either drug such as a high risk of bleeding or an autoimmune condition. The superiority of the combination over Nexavar (sorafenib), the current standard of care (SoC), was based on the results of the Phase III IMbrave150 study of patients with unresectable or metastatic HCC. In this study, the 12-month overall survival rate was 67.2% in the Avastin plus Tecentriq group compared with 54.6% in the Nexavar group. While median overall survival was not reached in this study, median progression-free survival increased from 4.3 months in the Nexavar group to 6.8 months in patients treated with Avastin plus Tecentriq.

Prior to approval of Roche’s combination of VEGF and PD-L1 inhibitors, the key strategy for first-line treatment of advanced HCC was multikinase inhibitors (TKIs), including Bayer’s Nexavar, which was approved in 2007 in Europe and 2008 in China, and Eisai’s Lenvima (lenvatinib), which was approved in 2018 in Europe and China. The approval of Avastin plus Tecentriq not only changed the SoC for HCC but also shifted the focus of R&D toward combination therapies. As a result, GlobalData expects the combination to change the HCC market landscape by capturing a dominant share of the market.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology